Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 274 results

Search Constraints

Start Over You searched for: Author "Stilgenbauer, Stephan" Remove constraint Author: "Stilgenbauer, Stephan" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
274 results on '"Stilgenbauer, Stephan"'

Search Results

1. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

2. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

3. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

4. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

5. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

7. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

9. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

10. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

11. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

12. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

13. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

14. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

15. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

18. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

19. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

23. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

24. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

26. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

27. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

29. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

30. Postibrutinib outcomes in patients with mantle cell lymphoma

31. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

32. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

34. CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

35. Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

36. Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

38. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

39. Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

41. Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

42. Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

44. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

45. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

46. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

47. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

Catalog

Books, media, physical & digital resources